Zafgen (ZFGN) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. NVDA
6. MSFT
7. SPY
8. SKYD
9. BBIO
10. RCKT

Go back to Zafgen (ZFGN) Tops Q2 EPS by 5c

Zafgen Reports Second Quarter 2015 Financial Results

August 11, 2015 4:01 PM EDT

Quarter Highlighted by Completion of Enrollment in bestPWS Phase 3 Clinical Trial - Six Month Data on Track for Release in Early Q1 2016

On Track to Report Data from Ongoing ZAF-203 Clinical Trial in Severe Obesity Complicated by Type 2 Diabetes in Late 2015/Very Early 2016

Ends Quarter with Cash and Marketable Securities of $220 Million

BOSTON, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced its second quarter... More